跳至主要内容
临床试验/JPRN-UMIN000035015
JPRN-UMIN000035015招募中未知

Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients with chronic liver disease - Efficacy of sodium-glucose co-transporter (SGLT2) inhibitor in chronic liver disease

Kitasato University School of Medicine0 个研究点目标入组 100 人开始时间: 2018年11月27日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Type 1 diabetes 2. Patients with severe ketosis or diabetic coma 3. Patients with diabetes insidious 4 Patients with Estimated Glomerular Filtration Rate (eGFR) of 45 mL / min / 1.73 m ^ 2 or less 5. Patients with malignancy 6. Patients with end-stage liver failure who have hepatic ascites, child-Pugh class BC and hepatic encephalopathy 7. Pregnant women or patients with potential pregnancy 8. Patients who research managers judged inappropriate as subjects

研究者

发起方
Kitasato University School of Medicine

相似试验

Efficacy and safety of sodium-glucose co-transporter... | 临床试验